Relay Therapeutics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 4 days.
- Recent price momentum is +67.2% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 19.9% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability F
How much profit the business keeps from each dollar of sales and capital.
| Operating margin | -1,971.6% | Better than 2% |
| Net margin | -1,800.6% | Better than 2% |
| Return on equity | -41.1% | Better than 10% |
| Return on invested capital | -42.6% | Better than 7% |
Momentum B+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -17.1% | Better than 36% |
| 6-month return | 19.1% | Better than 82% |
| 12-month return (ex latest month) | 168.5% | Better than 98% |
| Distance below 52-week high | 24.2% | Better than 52% |
Financial Health A+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 22.6x | Better than 98% |
| Debt to assets | 5.2% | Better than 79% |
Analyst View A
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 79.9% | Better than 78% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 15.91
- Open
- 15.59
- Day range
- 15.17 - 16.33
- Avg price
- 16.05
- Volume
- 3.98M
- Turnover
- 63.82M
- Turnover ratei
- 2.57%
- Volume ratioi
- 1.99
- Amplitudei
- 7.26%
- 52-week rangei
- 6.80 - 21.27
Valuation
- P/Ei
- -10.01
- P/E (TTM)i
- -10.75
- P/Bi
- 4.35
- EPSi
- -1.61
- Book value / shi
- 3.71
- Net profit
- -355.74M
- Net assets
- 819.10M
Share structure
- Market cap
- 3.56B
- Float capi
- 2.49B
- Shares out
- 220.96M
- Float sharesi
- 154.74M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2020-07-16
24.2% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-26.75M net over the window
Short interest
- Shares short
- 43.63M
- % of floati
- 19.91%
- Days to coveri
- 20.72
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Relay Therapeutics (RLAY)?
Relay Therapeutics last traded at 16.12. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Relay Therapeutics's market cap?
About 3.56B.
What is the P/E ratio of Relay Therapeutics?
The trailing twelve-month P/E is -10.75. The Valuation tab shows it against the stock's own five-year range.
Does Relay Therapeutics pay a dividend?
Relay Therapeutics does not currently pay a regular dividend.
Is Relay Therapeutics a buy according to analysts?
The consensus of 6 analysts is a Buy rating, with an average 12-month price target of 29.00, which implies 79.9% upside from the current price. This is not investment advice.
What is Relay Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Relay Therapeutics a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Relay Therapeutics discussion 0 comments